South Korea · Delayed Price · Currency is KRW Biotoxtech Statistics
Total Valuation
Biotoxtech has a market cap or net worth of KRW 52.74 billion. The enterprise value is 78.88 billion.
| Market Cap | 52.74B |
| Enterprise Value | 78.88B |
Important Dates
The last earnings date was Friday, March 27, 2026.
| Earnings Date | Mar 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biotoxtech has 15.72 million shares outstanding. The number of shares has decreased by -0.99% in one year.
| Current Share Class | 15.72M |
| Shares Outstanding | 15.72M |
| Shares Change (YoY) | -0.99% |
| Shares Change (QoQ) | -12.52% |
| Owned by Insiders (%) | 15.15% |
| Owned by Institutions (%) | n/a |
| Float | 10.36M |
Valuation Ratios
The trailing PE ratio is 45.34.
| PE Ratio | 45.34 |
| Forward PE | n/a |
| PS Ratio | 1.12 |
| PB Ratio | 1.65 |
| P/TBV Ratio | 1.36 |
| P/FCF Ratio | 11.68 |
| P/OCF Ratio | 7.95 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 67.84 |
| EV / Sales | 1.68 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 17.47 |
Financial Position
The company has a current ratio of 0.57, with a Debt / Equity ratio of 1.96.
| Current Ratio | 0.57 |
| Quick Ratio | 0.44 |
| Debt / Equity | 1.96 |
| Debt / EBITDA | n/a |
| Debt / FCF | 13.84 |
| Interest Coverage | -1.09 |
Financial Efficiency
Return on equity (ROE) is -4.74% and return on invested capital (ROIC) is -8.47%.
| Return on Equity (ROE) | -4.74% |
| Return on Assets (ROA) | -2.76% |
| Return on Invested Capital (ROIC) | -8.47% |
| Return on Capital Employed (ROCE) | -12.81% |
| Weighted Average Cost of Capital (WACC) | 7.04% |
| Revenue Per Employee | 250.09M |
| Profits Per Employee | 6.18M |
| Employee Count | 188 |
| Asset Turnover | 0.35 |
| Inventory Turnover | 3.75 |
Taxes
In the past 12 months, Biotoxtech has paid 1.23 billion in taxes.
| Income Tax | 1.23B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +10.18% in the last 52 weeks. The beta is 0.55, so Biotoxtech's price volatility has been lower than the market average.
| Beta (5Y) | 0.55 |
| 52-Week Price Change | +10.18% |
| 50-Day Moving Average | 3,189.70 |
| 200-Day Moving Average | 2,943.93 |
| Relative Strength Index (RSI) | 55.48 |
| Average Volume (20 Days) | 56,973 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Biotoxtech had revenue of KRW 47.02 billion and earned 1.16 billion in profits. Earnings per share was 74.00.
| Revenue | 47.02B |
| Gross Profit | 5.80B |
| Operating Income | -5.91B |
| Pretax Income | -345.70M |
| Net Income | 1.16B |
| EBITDA | -1.58B |
| EBIT | -5.91B |
| Earnings Per Share (EPS) | 74.00 |
Balance Sheet
The company has 28.13 billion in cash and 62.50 billion in debt, with a net cash position of -34.37 billion or -2,186.11 per share.
| Cash & Cash Equivalents | 28.13B |
| Total Debt | 62.50B |
| Net Cash | -34.37B |
| Net Cash Per Share | -2,186.11 |
| Equity (Book Value) | 31.93B |
| Book Value Per Share | 2,547.23 |
| Working Capital | -36.88B |
Cash Flow
In the last 12 months, operating cash flow was 6.64 billion and capital expenditures -2.12 billion, giving a free cash flow of 4.52 billion.
| Operating Cash Flow | 6.64B |
| Capital Expenditures | -2.12B |
| Depreciation & Amortization | 4.33B |
| Net Borrowing | -4.49B |
| Free Cash Flow | 4.52B |
| FCF Per Share | 287.22 |
Margins
Gross margin is 12.34%, with operating and profit margins of -12.57% and 2.47%.
| Gross Margin | 12.34% |
| Operating Margin | -12.57% |
| Pretax Margin | -0.74% |
| Profit Margin | 2.47% |
| EBITDA Margin | -3.35% |
| EBIT Margin | -12.57% |
| FCF Margin | 9.60% |
Dividends & Yields
Biotoxtech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.99% |
| Shareholder Yield | 0.99% |
| Earnings Yield | 2.20% |
| FCF Yield | 8.56% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Biotoxtech has an Altman Z-Score of 0.17 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.17 |
| Piotroski F-Score | 6 |